<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174276</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-330-1401</org_study_id>
    <secondary_id>2014-001011-39</secondary_id>
    <nct_id>NCT02174276</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, tolerability, and efficacy of GS-4774 in adults with
      chronic hepatitis B infection (CHB) and who are currently not on treatment. Participants will
      be randomized to receive tenofovir disoproxil fumarate (TDF) alone or GS-4774 plus TDF for 20
      weeks. After Week 20, GS-4774 will be discontinued. All participants will continue on TDF and
      will be followed for an additional 28 weeks. Following completion of the 48 week study
      period, all participants will be eligible for a 3 year registry study.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 21, 2014</start_date>
  <completion_date type="Anticipated">June 13, 2018</completion_date>
  <primary_completion_date type="Actual">February 17, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in serum hepatitis B surface antigen (HBsAg) from baseline to Week 24 (measured in log10 IU/mL)</measure>
    <time_frame>Up to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in serum HBsAg from baseline to Weeks 12 and 48 (measured in log10 IU/mL)</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HBsAg loss and HBsAg seroconversion at Weeks 24 and 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a ≥ 0.5 log10 or a ≥ 1.0 log10 decline in HBsAg at Weeks 12, 24, and 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with hepatitis B e antigen (HBeAg) loss and HBeAg seroconversion at Weeks 24 and 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with hepatitis B virus (HBV) DNA &lt; 20 IU/mL at Weeks 24 and 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of participants experiencing virologic breakthrough at Weeks 24 and 48</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Virologic breakthrough is defined as having confirmed HBV DNA ≥ 69 IU/mL after having been &lt; 69 IU/mL or HBV DNA ≥ 1 log10 IU/mL from nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug resistance mutations at Week 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>TDF 48 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive TDF for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF plus GS-4774 2 YU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TDF plus GS-4774 2 yeast units (YU) for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF plus GS-4774 10 YU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF plus GS-4774 40 YU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TDF plus GS-4774 40 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF</intervention_name>
    <description>300 mg tablets administered orally once daily.</description>
    <arm_group_label>TDF 48 weeks</arm_group_label>
    <arm_group_label>TDF plus GS-4774 2 YU</arm_group_label>
    <arm_group_label>TDF plus GS-4774 10 YU</arm_group_label>
    <arm_group_label>TDF plus GS-4774 40 YU</arm_group_label>
    <other_name>Viread®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GS-4774</intervention_name>
    <description>Administered as a subcutaneous injection every four weeks for a total of 6 doses</description>
    <arm_group_label>TDF plus GS-4774 2 YU</arm_group_label>
    <arm_group_label>TDF plus GS-4774 10 YU</arm_group_label>
    <arm_group_label>TDF plus GS-4774 40 YU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have the ability to understand and sign a written informed consent form, which
             must be obtained prior to initiation of study

          -  Documented evidence of chronic HBV infection (e.g., HBsAg positive for more than 6
             months)

          -  Screening HBV DNA ≥ 2000 IU/mL

          -  A negative serum pregnancy test is required for female subjects (unless surgically
             sterile or greater than two years post-menopausal)

        Key Exclusion Criteria:

          -  Cirrhosis

          -  Inadequate liver function

          -  Co-infection with hepatitis C virus (HCV), HIV or hepatitis D virus (HDV)

          -  Received antiviral treatment for HBV within 3 months of screening

          -  Evidence of hepatocellular carcinoma (e.g., as evidenced by recent imaging)

          -  Significant cardiovascular, pulmonary, or neurological disease

          -  Women who are pregnant or may wish to become pregnant during the course of the study

          -  Received solid organ or bone marrow transplant

          -  Received prolonged therapy with immunomodulators (e.g., corticosteroids) or biologics
             (e.g., monoclonal Ab, interferon) within 3 months of screening

          -  Use of investigational agents within 3 months of screening

          -  Current alcohol or substance abuse judged by the investigator to potentially interfere
             with subject compliance

          -  Receipt of immunoglobulin or other blood products within 3 months prior to enrollment

          -  History of demyelinating disease (Guillain-Barre), Bell's Palsy, Crohn's disease,
             Ulcerative colitis, or autoimmune disease

          -  Documented history of yeast allergy

          -  Known hypersensitivity to study drugs, metabolites or formulation excipients

          -  Malignancy within 5 years prior to screening, with the exception of specific cancers
             that are cured by surgical resection (basal cell skin cancer, etc). Subjects under
             evaluation for possible malignancy are not eligible

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Education, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silicon Valley Research Institute</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates, PA</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiaoli Ma, PC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Springfield</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon &amp; Leslie Diamond Health Care Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver and Intestinal Research Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital-The University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital-The University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou-S.Orsola-Malpighi - Universita Degli Studi Di</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea</name>
      <address>
        <city>Seocho</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Universiity</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Victor Babes Hospital for Infectious Diseases</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Boli Infectioase Prof.Dr. Matei Bals</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <disposition_first_submitted>January 27, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>January 27, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 30, 2017</disposition_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

